P - Caution when used during pregnancy
Nicergoline is an ergoloid mesylate derivative used to treat senile dementia and other disorders with vascular origins. It has been found to increase mental agility and enhance clarity and perception. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs.
It is used for vascular disorders such as cerebral thrombosis and atherosclerosis, arterial blockages in the limbs, Raynaud's disease, vascular migraines, and retinopathy.
Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.
It is marketed under the trade name Sermion.
Nicergoline is an ergot derivative. It has α-adrenergic blocking activity and produces vasodilatation.
Onset
1-1.5 hours(oral).
Absorption
Rapidly absorbed from the GI tract (oral).
Distribution
Protein-binding: 82-87%.
Metabolism
Undergoes significant 1st-pass effect.
Excretion
Via urine (80%), via faeces (20%).
Information Not Available
GI disturbances; hypotension (especially after parenteral admin). Hot flushes, malaise, hyperacidity, nausea, diarrhoea, dizziness, somnolence.
Information Not Available
Porphyria. Pregnancy.
May potentiate action of antihypertensives. May increase cardiac depressant effects of propranolol.
Information Not Available
Oral
Mental deterioration associated with cerebrovascular insufficiency
Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses.
Renal impairment: Reduce dose.
Oral
Peripheral vascular disease
Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses.
Renal impairment: Reduce dose.
Intravenous
Symptoms of mental deterioration associated with cerebrovascular insufficiency
Adult: 4-8 mg by slow IV infusion (over 30 minutes).
Renal impairment: Reduce dose.
Intravenous
Peripheral vascular disease
Adult: 4-8 mg by slow IV infusion (over 30 min).
Renal impairment: Reduce dose.
Intramuscular
Symptoms of mental deterioration associated with cerebrovascular insufficiency
Adult: 2-4 mg bid.
Renal impairment: Reduce dose.
Intramuscular
Peripheral vascular disease
Adult: 2-4 mg bid.
Renal impairment: Reduce dose.
Reconstitution
Dilute in 250 ml saline solution.
Should be taken on an empty stomach. (Take on an empty stomach.)
Caution when used during pregnancy
Information Not Available
Information Not Available
Information Not Available
Information Not Available
Information Not Available
Information Not Available
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.